MedPath

Norethisterone

Generic Name
Norethisterone
Brand Names
Activella 1/0.5 28 Day, Activelle, Alyacen 1/35, Alyacen 7/7/7, Amabelz 0.5/0.1 28 Day, Aranelle 28, Aurovela, Aurovela Fe, Aygestin, Balziva 28 Day, Blisovi 21 Fe 1.5/30 28 Day Pack, Blisovi 21 Fe 1/20 28 Day Pack, Blisovi 24 Fe 1/20 28 Day, Brevicon, Briellyn 28 Day, Camila 28 Day, Charlotte 24 Fe Chewable 28 Day, Combipatch, Cyclafem 1/35 28 Day, Cyclafem 7/7/7 28 Day, Cyonanz 28 Day, Dasetta 1/35 28 Day, Dasetta 7/7/7 28 Day, Deblitane 28 Day, Emzahh 28 Day, Errin 28 Day, Estalis, Etyqa 0.5/0.1 28 Day, Femcon Fe 28 Day, Femhrt 0.5/2.5 28 Day, Finzala 24 Fe Chewable 28 Day, Fyavolv, Gemmily 28 Day, Hailey 1.5/30 21 Day, Hailey 24 Fe 28 Day, Hailey Fe 1.5/30 28 Day, Hailey Fe 1/20 28 Day, Heather 28 Day, Incassia, Jencycla 28 Day, Jinteli, Junel 1.5/30 21 Day, Junel 1/20 21 Day, Junel Fe 1.5/30 28 Day, Junel Fe 1/20 28 Day, Junel Fe 24 1/20 28 Day, Kaitlib Fe 28 Day, Larin 1.5/30, Larin 1/20, Larin 24 Fe 1/20, Larin Fe 1.5/30, Larin Fe 1/20, Layolis Fe 28, Leena 28 Day, Lo Loestrin Fe 28 Day, Loestrin 1.5/30 21 Day, Loestrin 24 Fe 28 Day, Loestrin Fe 1/20 28 Day, Lolo, Lomedia 24 Fe, Lopreeza 1/0.5 28 Day, Lupaneta Pack 1-month, Lyleq 28 Day, Lyza, Melodetta 24 Fe Chewable 28 Day, Merzee 28 Day, Mibelas 24 Fe Chewable 28 Day, Microgestin 1.5/30 21 Day, Microgestin 1/20 21 Day, Microgestin 24 Fe 28 Day, Microgestin Fe 1.5/30 28 Day, Microgestin Fe 1/20 28 Day, Mimvey, Minastrin 24 Fe Chewable 28 Day, Myfembree, Necon 0.5/35 28 Day, Necon 1/35 28 Day, Necon 7/7/7 28 Day, Nexesta Fe 28 Day, Nora-BE 28 Day, Norlutate, Norlyda 28 Day, Norlyroc 28 Day, Nortrel 1/35 21 Day, Nortrel 1/35 28 Day, Nortrel 7/7/7 28 Day, Nylia 1/35 28 Day, Nylia 7/7/7 28 Day, Oriahnn 28 Day Kit, Ortho Micronor, Ortho Micronor 28 Day, Ortho-novum 7/7/7 28 Day, Philith 28 Day, Pirmella 1/35 28 Day, Pirmella 7/7/7 28 Day, Rhuzdah 28 Day, Select, Sharobel 28 Day, Synphasic, Tarina 24 Fe 1/20 28 Day, Tarina Fe 1/20 28 Day, Taysofy 28 Day, Taytulla 28 Day, Tilia Fe, Tri-legest 28 Day, Tulana 28 Day, Vyfemla 28 Day, Wera 28 Day, Wymzya Fe 28 Day, Zenchent
Drug Type
Small Molecule
Chemical Formula
C20H26O2
CAS Number
68-22-4
Unique Ingredient Identifier
T18F433X4S
Background

Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with levonorgestrel and its derivatives, and is the active form of several other progestins including norethynodrel and lynestrenol. Norethisterone mimics the actions of endogenous progesterone, albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy. First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962.

Indication

Norethisterone is indicated as an oral contraceptive when given as monotherapy or in combination with an estrogen component, such as ethinylestradiol or estradiol. In combination with an estrogen component, oral norethisterone is also indicated as a hormone replacement therapy in the treatment of postmenopausal osteoporosis and moderate-to-severe vasomotor symptoms arising from menopause. When applied via transdermal patch, the combination of norethisterone and estradiol is indicated for the treatment of hypoestrogenism, vulvovaginal atrophy, and moderate-severe vasomotor symptoms.

Norethisterone, taken in combination with intramuscular leuprolide, is also indicated for the symptomatic treatment of endometriosis-related pain.

Associated Conditions
Endometriosis related pain, Heavy Menstrual Bleeding, Moderate to Severe Vasomotor Symptoms, Osteoporosis, Postmenopausal Osteoporosis, Severe Pain, Vulvo Vaginal Atrophy, Hypoestrogenism, Moderate, severe, Vasomotor Symptoms caused by Menopause
Associated Therapies
Contraception, Hormone Replacement Therapy, Oral Contraceptives

Ovulation Incidence in Oral Contraceptive Users

Phase 3
Suspended
Conditions
Contraception
Ovulation
Interventions
First Posted Date
2017-04-10
Last Posted Date
2024-12-11
Lead Sponsor
University of Southern California
Target Recruit Count
58
Registration Number
NCT03106454
Locations
🇺🇸

Brian T. Nguyen, Los Angeles, California, United States

The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis

Phase 4
Completed
Conditions
Bacterial Vaginosis
HIV
Interventions
First Posted Date
2016-09-19
Last Posted Date
2020-03-12
Lead Sponsor
London School of Hygiene and Tropical Medicine
Target Recruit Count
250
Registration Number
NCT02905890
Locations
🇺🇬

MRC/UVRI Mengo Clinic and Research Station, Kampala, Uganda

A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2016-01-12
Last Posted Date
2016-06-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
18
Registration Number
NCT02652650

Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study

Phase 2
Completed
Conditions
Endometriosis
Interventions
First Posted Date
2015-09-07
Last Posted Date
2020-02-05
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
10
Registration Number
NCT02542410
Locations
🇺🇸

Children's Hospital Boston, Boston, Massachusetts, United States

Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant

Not Applicable
Completed
Conditions
Etonogestrel Contraceptive Implant, Bothersome Bleeding
Interventions
First Posted Date
2015-02-02
Last Posted Date
2022-03-16
Lead Sponsor
Norton Healthcare
Target Recruit Count
88
Registration Number
NCT02353247
Locations
🇺🇸

Kosair Children's Hospital, Louisville, Kentucky, United States

Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325

Phase 1
Completed
Conditions
Hepatitis C
Interventions
Drug: FDC of Daclatasvir, Asunaprevir and BMS-791325
First Posted Date
2014-04-04
Last Posted Date
2014-08-15
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
20
Registration Number
NCT02103569

Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

Phase 2
Completed
Conditions
Heavy Uterine Bleeding
Uterine Fibroids
Interventions
First Posted Date
2013-03-25
Last Posted Date
2020-07-21
Lead Sponsor
AbbVie
Target Recruit Count
571
Registration Number
NCT01817530

Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women

Phase 4
Completed
Conditions
Healthy
Menopause
Interventions
First Posted Date
2012-10-12
Last Posted Date
2017-02-28
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
191
Registration Number
NCT01705249
Locations
🇸🇪

Novo Nordisk Investigational Site, Uddevalla, Sweden

The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception

Not Applicable
Completed
Conditions
Pregnancy
HIV
AIDS
Interventions
First Posted Date
2012-08-17
Last Posted Date
2015-08-20
Lead Sponsor
University of Southern California
Target Recruit Count
35
Registration Number
NCT01667978
Locations
🇺🇸

Los Angeles County Hospital University of Southern California (LAC USC), Los Angeles, California, United States

🇺🇸

Los Angeles County University of Southern California, Los Angeles, California, United States

Investigation of 2 Different Oral Formulations of Estradiol and Norethisterone in Healthy Women

Phase 1
Completed
Conditions
Menopause
Healthy
Interventions
First Posted Date
2012-05-10
Last Posted Date
2015-03-18
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
44
Registration Number
NCT01596010
© Copyright 2025. All Rights Reserved by MedPath